Small-cap biotech mania continues 🚀

In the wake of Fed Day!                                                                                                                                                                                                                                                                                                                                                                                                                 December 13, 2023 (new) [Blowout]( 🥳 I [Bullseye Cranking]( 🎯 I [Futures Closing Soon]( *Sponsored by Coeptis Therapeutics Holdings, Inc. Happy “Fed Day”! Unless you were hanging out under a rock yesterday 🪨, you heard the great news that, once again, the CPI report came in line with expectations. 📉 Is inflation firmly under control right now? Is it only a matter of time before the Fed starts to cut rates again? One never knows but it appears this possibility has been driving stock prices higher… including these big movers inside! Keep reading and being the best prepared trader on the Street! FOCUS LIST STTK - Up over 30% in pre-market after positive Phase 1 results in Acute Myeloid Leukemia (AML) treatment CCCC - Up over 15% in pre after closing yesterday up over 98%, and reporting Phase 1 data in after-hours RSLS - Up over 40% in pre after receiving FDA PMA supplement approval for new weight loss product 🔥Hot Stock of the Day🔥 *Sponsored by Coeptis Therapeutics Holdings, Inc. Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) Coeptis is a clinical-stage biopharma company based in Wexford, PA, that’s set out on a very bold mission to revolutionize cancer therapy. The stock has a history of powerful swings, including a 33% jump in two weeks early last month, and then another 15% rally just after that. It’s drawn back since then, but what’s happened over the last week is what interests me most… As you can see here, the stock refuses to drop beneath a $1.00 floor and has traded ultimately sideways. Why we love this setup: It’s a strong hint that the bottom is in and that we could be looking at a serious upswing in the near term. And if the analysts are right. That swing could be very dramatic. Just look at how fast the reversals have been.  That is why we think it is imperative you get COEP on your radar right away. As always, make sure you enter every trade you make with a solid understanding of the risk you are taking and only enter trades that you have a good risk-defined strategy. For a deeper dive, you can [watch the COEP investor presentation]( from last week to review what the company’s all about. *This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. HOTLIST STTK - Up over 90% in pre-market after positive Phase 1 results in Acute Myeloid Leukemia (AML) treatment Shattuck Labs (STTK) is a clinical-stage biotechnology company that develops therapeutics for the treatment of cancer and autoimmune disease in the United States. Early this morning, the [company announced positive initial topline data]( from its ongoing phase 1 a/b n clinical trial of sl-172154 with Azacitidine in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and tp53 mutant (tp53m) Acute Myeloid Leukemia (AML) patients. The stock is trading around 90% higher in pre-market after the news, after initially exploding up over 200%. The $4.50 area has acted as resistance in pre-market and will be an important level to watch. Above it, targets to the upside are $5, $6, $6.74 and then the pre-market high at $7.28. Beyond that, $8 and $9 come into play. Below $4.50, there is potential support at $4, $3.75, $3 and then $2.20, with a gap to fill at $2.11. CCCC - Up over 15% in pre after closing yesterday up over 98%, and reporting Phase 1 data in after-hours C4 Therapeutics (CCCC) is a clinical-stage biopharmaceutical company that develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Yesterday morning, [the company announced]( a license and research collaboration with Merck for degrader-antibody conjugates. The company stated it would receive $10m upfront payment and is eligible for milestone payment of $600m. The stock closed up over 98% after the news. Additionally, in the after-hours, [CCCC reported positive data]( from its CFT7455 Phase 1 trial in Relapsed/Refractory Multiple Myeloma. The stock is in play again today after record volume yesterday and is gapping up another 15% in the pre-market this morning. $2.50 has acted as support so far in the pre-market and will be an important level to watch. Above $2.50, the first target to the upside is $3 and then the pre-market high at $3.46. Beyond that, $3.90, $4.50 and $5 come into play. Below $2.50, there is potential support at $2.15, $2, $1.70, and a gap to fill at $1.18. RSLS - Up over 40% in pre after receiving FDA PMA supplement approval for new weight loss product ReShape Lifesciences (RSLS) is a medical device company that provides products and services that manage and treat obesity and metabolic diseases in the United States and internationally. In the after-hours yesterday, [the company announced]( that it had received FDA PMA supplement approval for its next-generation Lap-Band® 2.0 flex. This is a new and improved weight loss device designed to help patients with weight loss. The stock is trading up over 40% in the pre-market after the news. The $0.34 area has acted as support so far in the pre-market and will be an important level to watch. Above it, targets to the upside are $0.38 and then the after-hours high at $0.4230. Beyond that $0.50, $0.60 and $0.80 come into play. Below $0.34, there is potential support at $0.32, $0.29 and then a gap to fill at $0.25.10. MARKET NEWS POLL: VOTE! The Lakers just won the first ever NBA in-season tournament… [Lebron’s getting another chip]( [The Milwaukee Bucks are my pick or the Denver Nuggets]( [I only care about the Dallas Cowboys, stop asking me these other sports questions]( Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull Disclaimer *ISSUE-PAID ADVERTISEMENT. RagingBull has currently been paid fifteen thousand dollars by ach bank transfer by Coeptis Therapeutics Holdings, Inc from a period beginning on December 13, 2023 through December 15 of the same year. Previously, RagingBull was paid nineteen thousand dollars by ach bank transfer by Lifewater Media for advertising Coeptis from a period beginning on June 7, 2023 through June 8 of the same year. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of Raging Bull, do not hold a position in Coeptis Therapeutics Holdings, Inc. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Coeptis Therapeutics Holdings, Inc, increased trading volume, and possibly an increased share price of the Coeptis Therapeutics Holdings, Inc securities, which may or may not be temporary and decrease once the marketing arrangement has ended. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull can guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https:// www. sec. gov/edgar/searchedgar/companysearch TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. WE MAY HOLD SECURITIES DISCUSSED. Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2023 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States of America